Inaba Takumi, Yamamoto Yu, Hirayama Kaho, Kobayashi Takuma, Izumi Naoto, Sakamoto Hirotsugu, Hatakeyama Shuji, Matsumura Masami
Division of General Internal Medicine, Jichi Medical University Hospital, Japan.
Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan.
Intern Med. 2025 Mar 15;64(6):845-849. doi: 10.2169/internalmedicine.4105-24. Epub 2024 Aug 10.
Hydroxycarbamide, an antimetabolic agent used to treat myeloproliferative disorders, causes side effects, including myelosuppression, skin ulcers, and oral mucositis. Gastrointestinal ulcers are uncommon, and esophageal ulcers have not been previously reported. We present the case of a 74-year-old woman who developed esophageal and ileal ulcers after hydroxycarbamide treatment. Our case and previous reports suggest that hydroxycarbamide can cause ulcers throughout the gastrointestinal tract, which can improve rapidly after discontinuing medication. When new signs and symptoms occur, drug-induced etiologies should be considered as a potential cause. Timely diagnostic treatment with discontinuation of medication is crucial in such cases.
羟基脲是一种用于治疗骨髓增殖性疾病的抗代谢药物，会引起包括骨髓抑制、皮肤溃疡和口腔黏膜炎在内的副作用。胃肠道溃疡并不常见，此前也未报道过食管溃疡。我们报告了一例74岁女性在接受羟基脲治疗后出现食管和回肠溃疡的病例。我们的病例及既往报告表明，羟基脲可导致全胃肠道溃疡，停药后溃疡可迅速改善。当出现新的体征和症状时，应考虑药物性病因作为潜在原因。在此类病例中，及时诊断并停药治疗至关重要。
